Member Info for mact4

Yes Synairgen should get data from Phase 2. This is from the NIH site:

"Unblinded Day 28 data will also be provided to a small group of people from the company who owns the investigational agent, to assist the company in deciding if the agent should move into phase 3 evaluation; or in choosing a dose of their agent to move into phase 3 evaluation."
- from: https://clinicaltrials.gov/ct2/show/NCT04518410

I agree; RM and his team have stayed true to their principles that data is king.

In the meantime, we just have to hold fast through the gyrations of the SP. FWIW SP still looks to be in a consolidating triangle formation. This is one of the most frustrating chart pattern as it takes a looong time to resolve, but when it does, whoopee. Fireworks.

"Everyone likes to talk up their own book, as they say."

Synairgen is the exception!

Chart wise, it’s not a surprise to me that price has dropped a little today. There is a short/term downward slope acting as resistance. SP hit this trend line yesterday and the retreat started.
Longer term - not much changed. Just the usual prove movement.

Because it is the weekend ... and projecting SP is less depressing than seeing the current SP stuck in a zone (monthly chart shows a consolidating triangle/pennant pattern, awaiting breakout).

The high of May 2020 (77.54) is a 3.618 Fibonacci extension of a small impulse wave 1 (low of 8/17 to high of 7/18).
The high of Aug 2020 (258.46) is a confluence of Fib extension wave 1 (factor of 13) and of next impulse wave 3 (low of 8/17 to high of 5/20) - Fib factor of 3.618.

Projecting forward, there are now 3 impulse waves to look for confluence but two confluence points are of particular interest: circa 325 and circa 915.

Additional price zones of potential interest: circa 413 and circa 665.

If Synairgen becomes the runaway success that it should be, these will not be the end points, merely 'pause' price zones.

Look at the submission date for this Indian article. In relative terms, it is 'old'.

Where will these shares land? Will Polygon add to their holding? Hmmm.

Just heard from a relative: ICU beds full in Houston.
That’s just one city

Far as I could see, data set of just over 200!

Preorder prices treatment at $700 each.

Message delivered, gun. Yours is a potential scenario and up to you to decide what you wish to do based on your own research. No need to dwell any further.

BTW - your comments would have more weight if you kept to one username and accept the criticism and the support, like most of us here.

No ellipsis so can't be Org. Not Tigger as no mention of financial adviSe !

@Kiwi: they are trying harder to deramp - quite a substantial post for a first post :-)

Matterhorn, my poor brain can't take in all this data. I had to sleep on the conversation between Dudio and Ghia to process their discussion!

Is your opinion that the more up-to-date protocol more beneficial to SNG001?

Nice confident opening SP. Woo hoo!

It is an undisputed fact. We are getting closer to results each day - time flow is linear and one-directional! :-)

Dudio, you may be right that meta analysis of both sets of data will give a better and clearer reading for SNG001. It would certainly be a positive move.

There is one big difference between both trials (maybe the experts here can confirm. I must admit to getting somewhat easily confused with the different trials!).

Inclusion in for the SNG016 home trial, only required a positive Covid test and a risk factor.
Activ2 inclusion requires a lot more including breathlessness (criteria 3 in a long list of acceptable symptoms) ie giving SNG001 more of 'a fire to put out'

Well, there are always caveats. So long as price does not take touch 153, my short-term analysis holds.
That being the case, we should soon be working towards a new 'high '. Fibonacci price points of interest: 174, 181 or further afield: 202 and 223.

Even as I write, price is dropping to 154 so I would refer you back to my caveat at the start! ;-)

Possibly why SNG001 is found to have max impact on those who are breathless, or in the words of RM (paraphrased): SNG001 needs a fire to put out.

@Doc I was not going to say anything but you asked for it!

In the SHORT-term, if the current move (from the high of 3/8 is a corrective move (looking like one at the moment), then price could retrace to the 154 zone before moving north again.

Medium term - I am looking at an upward sloping channel with two possible top trend lines. A very positive RNS (aka with a £B preorder will blow through top of both channels. Anything else will see SP hit one or both these upper trendlines and drift back to lower support until more news arrive.

FTC
My apologies for offending you. At first glance £2500 seems small for a seasoned investor of 35 years.
But after your last post, I can clearly see that your view on risk and many others here, are vastly different. BUT appropriate for you.